BioMark Diagnostics Inc C.BUX

Alternate Symbol(s): BMKDF

Healthcare Biotechnology

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat cancers. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. Its oncology has developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.

CSE:BUX - Post by User

BioMark Diagnostics Inc

Bullboard Posts

Comment by David8888on Nov 04, 2017 5:51pm

94 Views

Post# 26906869

RE:Original PP priced at .15 and more recent PP priced .....

I question the wisdom of unloading at just a blip over the warrant price unless the warrants were going to expire within a short period of time.

Again, the smart thing for the company to do is increase promotion and get long term shareholders on board that will see Biomark through to a buy-out or commercialization JV.

The difference is making pennies vs exponential gains.

Bullboard Posts

BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma-In-Situ: A Patient's Guide